Seattle Genetics, Laureate Pharma form manufacturing agreement

By Lisa Kerner

Erie, Pa., April 25 - Seattle Genetics, Inc. entered into an agreement with Laureate Pharma, Inc. for manufacturing of the company's SGN-33 and SGN-70 monoclonal antibody product candidates.

Laureate will perform scale-up and manufacturing of the products to support clinical trials, according to an 8-K filed with the Securities and Exchange Commission.

The total costs for the manufacture of SGN-33 and SGN-70, including raw materials and fill/finish, may top $5.7 million.

Seattle Genetics is a Bothell, Wash., biotechnology company developing monoclonal antibody (mAb)-based therapeutics for cancer and immunologic diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.